Dante Genomics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Dante Genomics's estimated annual revenue is currently $29.3M per year.(i)
  • Dante Genomics's estimated revenue per employee is $193,750

Employee Data

  • Dante Genomics has 151 Employees.(i)
  • Dante Genomics grew their employee count by 5% last year.

Dante Genomics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-20%N/AN/A
#2
$6.7M438%N/AN/A
#3
$34.4M222-1%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.3M2-50%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$3.6M230%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

What Is Dante Genomics?

Dante Genomics is a leading global genomics and precision medicine company working to deliver better healthcare and save lives with a more human approach to health. \nWe work with customers across 97 countries and we create customized genomic analysis processes that have an impact on people’s lives. \n\nOur mission is to accelerate science for the people. We leverage genome sequencing technology and interpretation so that everyone can make informed decisions about their health and their future.\n\nWe use the proprietary genomic platform, based on artificial intelligence and machine learning, capable of integrating and optimizing all resources and information, creating important synergies for our stakeholders. We also collaborate with international associations and advocacy groups to find solutions to improve the quality of life of patients.\n\nIn 2019 the two founders won the EY award as \best entrepreneurs of the year\ and the company took sixth place in the list of 2023 growth leaders compiled by Statista and Il Sole 24 Ore.\n\nMore information is available at www.dantegenomics.com

keywords:N/A

N/A

Total Funding

151

Number of Employees

$29.3M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$24.1M15137%N/A
#2
$37.7M151-1%N/A
#3
$24.3M1510%N/A
#4
$26.6M151N/AN/A
#5
$24.1M1519%N/A